

## CaMKII (pThr286 or 287) pAb serum

**Quality Control Certificate of Analysis** Catalogue No.: A010-50 Unit Size: 20 µl Lot No: 0412-05

Background: Ca2+/calmodulin-dependent kinase II (CaMKII) is a ubiquitous, multifunctional serine/threonine kinase involved in translating Ca<sup>2+</sup>- transient signals into cellular responses (Shulman & Braun, 1999). Four separate CaMKII genes are expressed in man ( $\alpha$ ,  $\beta$ ,  $\delta$ ,  $\gamma$ ) with isoforms within each gene. CaMKII δ and γ are abundant in the heart. CaMKII is activated by Ca<sup>2+</sup>/CaM binding, and becomes activated for prolonged periods of time following autophosphorylation of Thr-286 or Thr-287 (equivalent residues in different isoforms). This antibody recognizes the active, autophosphorylated enzyme (all isoforms) and thus can measure the abundance of active CaMKII. Prolonged activation of CaMKII is associated with a variety of vascular and cardiac diseases including stroke (Vest et al., 2010), atrial fibrillation (Dobrev & Wehrens, 2010) cardiac arrhythmia & sudden death (van Oort et al., 2010), cardiac apoptosis (Wang et al., 2004), and heart failure (Erickson et al., 2011).

Description: Lyophilised Rabbit polyclonal anti-serum to CaMKII Phospho Thr-286/287 (A010-50).

Immunogen: Synthetic peptide (M<sub>281</sub>HRQET(PO<sub>3</sub>H<sub>2</sub>)VDC<sub>289</sub>) corresponding to amino acids surrounding the phosphorylated threonine residue at position 286 (or 287) of CaMKII, which was conjugated to keyhole limpet hemocyanin (KLH) by carbodiimide cross linkage.

Antibody Isotype: IgG.

Antibody Purity: Raw Serum.

**Specificity:** The antibody recognises both of the  $\alpha$  and  $\beta$  subunits of CaMKII when phosphorylated at Thr-286. Binding of the antibody to its target epitope is blocked in the presence of a phosphopeptide containing the CaMKII Phospho Thr-286 epitope.

Species Cross Reactivity: Reacts with rat. Not yet tested in other species. However, from primary sequence analysis, the antibody will recognise Phospho Thr-286 (or 287) in all isoforms ( $\alpha$ ,  $\beta$ ,  $\gamma$  and  $\delta$ ) from human, rat and mouse. The antibody is also expected to react with various isoforms from chicken, cow, pig, rabbit, zebrafish, and Xenopus laevis

Vial Constituents: Lyophilised A010-50 Rabbit anti-serum (20 µl)

Storage Instructions: Lyophilised antibody is stable at 4°C when stored with desiccant. Reconstitute lyophilised powder in 20 µl of 18 MΩ H<sub>2</sub>O, aliquot and store frozen at -80°C for 1 year. Avoid freeze - thaw cycles.

Tested Applications: WB 1:5000. Not yet tested in other applications, therefore, optimal dilutions/concentrations should be determined by the user.

	PO <sub>3</sub> H <sub>2</sub> Specific							
	280		.↓			290		
Epitope	-MH	R	QE	т	۷	D	C	-
Human	СМН	R	QE	т	۷	D	С	L
Mouse	СМН	R	QE	т	۷	D	С	L
Rat	MMH	R	QE	т	۷	E	С	L
Xenopus	СМН	R	QE	т	۷	D	С	L
Drosophila	VVH	R	QE	Т	۷	D	C	L

ALL REAL PROPERTY IN THE REAL PROPERTY INTO THE REAL PR ABR I MW kDa 175 83 62 47 32. + 1µM peptide + 10µM peptide

A010-50 (1:5000) 1 µl in 5 ml of Tris buffer + 5% milk powder 16 hours at 4°C

Secondary antibody = Goat anti Rabbit HRP Chemiluminescent detection

Lane 1: 50 µg of Rat Brain Extract incubated with Ca<sup>2+</sup> + Calmodulin Lane 2: 50 µg of RatBbrain Extract incubated with Ca<sup>2+</sup> + Calmodulin + ATP Lane 3+4: Identical to lanes 1+2 Lane 5+6: Identical to lanes 1+2

WB using 1:5000 CaMKII Phospho threonine-286 anti-serum (A010-50)

against 50µg of Rat Brain Extract incubated for 1 minute at 30°C with Ca2+, Calmodulin +/- MgATP. CaMKII anti-serum detected α and β kinase subunits in brain samples incubated with ATP. The staining was inhibited in Identical A010-50 blots through the addition of 1uM and 10uM immunising peptide.12% SDS-PAGE gel. PVDF membrane.

## **Related Products:**

CaMKII Phospho Thr-286 epitope peptide (P010-50), CaMKII Phospho Thr-286 Affinity Purified Antibody (A010-50AP)

- Background References: Dobrev, D., & Wehrens, X.H.T. (2010) Trends in Cardiov. Medicine 20, 30-34 Erickson, J.R., He, B.J., Grumbach, I.M., & Anderson, M.E. (2011) CaMKII in the cardiovascular system: sensing redox states. Physiol. Rev. 91, 889-915. Van Oort, R.J. et al. (2010) Circulation 122, 2669-79
- Shulman, H. & Braun, A.P. (1999) in Caratoli E. & Klee, C. (Eds.) Calcium as a Cellular Regulator, Oxford University Press.
  Vest, R. S., O'Leary, H., Coltrap, S.J., Kindy, M.S., & Bayer, K.L. (2010) Effective post-insult neuroprotection by a novel Ca2+/Calmodulin-dependent protein kinase II (CaMKII) inhibitor. J.
- Wang, W., Zhu, W., Wang, S., Yang, D., Crow, M.T., Xiao, R-P. & Cheng, H. (2004) Sustained b1-adrenergic stimulation modulates cardiac contractility by Ca2+/calmodulin kinase signaling
  Wang, W., Zhu, W., Wang, S., Yang, D., Crow, M.T., Xiao, R-P. & Cheng, H. (2004) Sustained b1-adrenergic stimulation modulates cardiac contractility by Ca2+/calmodulin kinase signaling
- pathway. Circ. Res. 95, 798-806

Badrilla Ltd. Leeds Innovation Centre, 103 Clarendon Road, Leeds LS2 9DF, UK. Tel: +44 (0)7801 730618. Email: info@badrilla.com